Harmony Biosciences Files 8-K on Shareholder Vote Matters

Ticker: HRMY · Form: 8-K · Filed: 2024-05-29T00:00:00.000Z

Sentiment: neutral

Topics: shareholder-vote, corporate-governance

Related Tickers: HRMY

TL;DR

Harmony Biosciences held a shareholder vote, details to follow.

AI Summary

Harmony Biosciences Holdings, Inc. filed an 8-K on May 29, 2024, to report on matters submitted to a vote of its security holders. The filing does not detail the specific proposals voted on or the outcomes.

Why It Matters

This filing indicates that Harmony Biosciences held a shareholder meeting where important decisions were made, the details of which will be crucial for understanding the company's future direction.

Risk Assessment

Risk Level: low — The filing is procedural and does not contain new financial or operational risks.

Key Players & Entities

FAQ

What specific matters were submitted to a vote of Harmony Biosciences' security holders?

The filing does not specify the exact proposals voted on, only that matters were submitted to a vote.

When did the event related to the shareholder vote occur?

The earliest event reported was on May 29, 2024.

What is Harmony Biosciences' principal executive office address?

The address is 630 W. Germantown Pike, Suite 215, Plymouth Meeting, PA 19462.

What is Harmony Biosciences' IRS Employer Identification Number?

The IRS number is 82-2279923.

Under which section of the Securities Exchange Act of 1934 is this Form 8-K filed?

This Form 8-K is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

From the Filing

0001558370-24-008734.txt : 20240529 0001558370-24-008734.hdr.sgml : 20240529 20240529170117 ACCESSION NUMBER: 0001558370-24-008734 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240529 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20240529 DATE AS OF CHANGE: 20240529 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Harmony Biosciences Holdings, Inc. CENTRAL INDEX KEY: 0001802665 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 822279923 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39450 FILM NUMBER: 24999420 BUSINESS ADDRESS: STREET 1: 630 W GERMANTOWN PIKE STREET 2: SUITE 215 CITY: PLYMOUTH MEETING STATE: PA ZIP: 19462 BUSINESS PHONE: (484) 539-9800 MAIL ADDRESS: STREET 1: 630 W GERMANTOWN PIKE STREET 2: SUITE 215 CITY: PLYMOUTH MEETING STATE: PA ZIP: 19462 8-K 1 hrmy-20240529x8k.htm 8-K 0001802665 false 0001802665 2024-05-29 2024-05-29 ​ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ​ FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ​ Date of report (Date of earliest event reported): May 29, 2024 ​ HARMONY BIOSCIENCES HOLDINGS, INC . (Exact name of registrant as specified in its charter) ​ ​ ​ ​ Delaware 001-39450 82-2279923 (State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No.) ​ 630 W. Germantown Pike , Suite 215 Plymouth Meeting , PA 19462 (Address of principal executive offices) (Zip Code) ( 484 ) 539-9800 (Registrant’s telephone number, including area code) N/A (Former name or former address, if changed since last report.) ​ Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ​ ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ​ ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ​ ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) ​ Securities registered pursuant to Section 12(b) of the Act: ​ ​ ​ ​ ​ ​      Trading      Name of each exchange Title of each class ​ Symbol(s) ​ on which registered Common Stock, $0.00001 par value per share ​ HRMY ​ The Nasdaq Global Market ​ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ​ Emerging growth company ☐ ​ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ ​ ​ ​ ​ Item 5.07. Submission of Matters to a Vote of Security Holders. ​ On May 29, 2024, Harmony Biosciences Holdings, Inc. (the “Company”) held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”). A total of 40,712,810 shares of the Company’s common stock were represented in person or by proxy, constituting a quorum. At the Annual Meeting, stockholders voted on the following two proposals, each of which is described in detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April

View on Read The Filing